Search
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.
The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.
An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.
Researchers gain insight into leptomeningeal metastasis, a devastating complication of advanced cancer.
Memorial Sloan Kettering Cancer Center (MSK) and Curadev Pharma, Inc., a biotechnology company developing novel immuno-oncology therapeutics, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874-SI, Curadev’s first-in-class allosteric stimulator of interferon genes (STING) agonist for solid tumors.
Minimally invasive techniques, improved postoperative care, and a multidisciplinary approach help make Memorial Sloan Kettering Cancer Center’s rates of esophageal surgical morbidity and mortality among the country’s lowest.
The Lehigh Valley Health Network (LVHN) Cancer Institute is now a formal member of the Memorial Sloan Kettering (MSK) Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for people with cancer in community healthcare settings. Representatives of both organizations made the announcement today at Lehigh Valley Hospital–Cedar Crest following an intensive six-month collaborative review process.
Learn about a heartburn-related condition called Barrett’s esophagus and its connection to a higher risk of esophageal cancer.
Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.
By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.